Mobile app to support patients with multiple myeloma
Official title: Randomized Controlled Trial of a Psychosocial Mobile Application (THRIVE-M) for Patients Living With Multiple Myeloma
Run by Massachusetts General Hospital · NCT06073353 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a mobile app called THRIVE-M to see if it can help people with multiple myeloma feel better and cope with their condition compared to regular care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT06073353 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with newly diagnosed, maintenance, or relapsed multiple myeloma.
✕Probably not a fit
Patients with acute or unstable psychiatric or cognitive conditions that hinder informed consent or compliance may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the effectiveness of a psychosocial mobile application called THRIVE-M in improving quality of life, reducing psychological distress, and alleviating fatigue in patients with multiple myeloma compared to standard care. The study addresses the psychological burden faced by these patients, who often experience significant morbidity due to their condition. By utilizing validated questionnaires, the trial will measure various patient-reported outcomes, including coping strategies and self-efficacy. The goal is to provide a tailored, innovative solution to enhance the psychosocial support available to this patient population.
Why it matters
Potential benefit: If successful, this intervention could significantly improve the psychological well-being and overall quality of life for patients living with multiple myeloma.
How similar studies have gone: While psychosocial interventions for cancer patients are common, this specific mobile application approach for multiple myeloma is novel and has not been previously tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (aged 18 years or older) with one of the following diagnoses: 1. newly diagnosed multiple myeloma receiving first-line therapy, 2. multiple myeloma on maintenance therapy, or 3. relapsed multiple myeloma receiving 2nd or 3rd line therapy * Ability to comprehend, read, and respond to questions in English Exclusion Criteria: - Patients with acute or unstable psychiatric or cognitive conditions that the treating clinicians believe prohibit informed consent or compliance with study procedures
Where it's running
-
Massachusetts General Hospital
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Areej El-Jawahri, MD — Massachusetts General Hospital
- Study coordinator: Areej El-Jawahri, MD
- Email: ael-jawahri@mgb.org
- Phone: 617-724-4000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
6MW5311 in adults with relapsed or refractory blood cancers
This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma
In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.
-
Exercise phenotyping before chemotherapy in newly diagnosed multiple myeloma
This observational study tests whether some newly diagnosed multiple myeloma patients with normal resting heart function already show limited exercise capacity, and whether that limitation relates to subtle heart tissue changes and future heart-related outcomes.
-
SMS text check-ins to track symptoms for people with plasma cell disorders
This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.
-
Cevostamab with Pomalidomide and Dexamethasone after BCMA-directed CAR T therapy in multiple myeloma
This study tests if Cevostamab combined with pomalidomide and dexamethasone can help people with multiple myeloma who have already had CAR T therapy and several prior treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.